Latest From the NEOTORCH Trial & KEYNOTE-671 Trial

EP: 1.Treatment Approaches for Early-Stage Lung Cancer

EP: 2.Driving Precision Medicine Through Molecular Testing in NSCLC

EP: 3.Neoadjuvant/Perioperative Immunotherapy in NSCLC

EP: 4.Referral of Early-Stage NSCLC to Multidisciplinary Teams

EP: 5.Neoadjuvant, Adjuvant, and Perioperative Options in NSCLC

EP: 6.Updates in CheckMate-816 From ESMO 2023

EP: 7.AEGEAN Trial: Perioperative Approach in NSCLC

Now Viewing

EP: 8.Latest From the NEOTORCH Trial & KEYNOTE-671 Trial

EP: 9.CheckMate-77T Trial Results From ESMO 2023

EP: 10.Treatment Decision Making by Stage for Resectable NSCLC

EP: 11.The Emerging Role of ctDNA in NSCLC Management

EP: 12.Addressing Gaps in Care for Non-Small Cell Lung Cancer

This is a video synopsis/summary of a Precision Medicine featuring Patrick Forde, MBBCh, and Tina Cascone, MD, PhD.

Forde and Cascone discuss 2 additional perioperative treatment options for non–small cell lung cancer (NSCLC) from the NEOTORCH study and the KEYNOTE-671 trial.

The NEOTORCH trial, conducted predominantly in China, evaluated the anti-PD1 agent toripalimab. Patients received 3 cycles of chemotherapy plus immunotherapy preoperatively, followed by an additional cycle postoperatively and maintenance toripalimab. The results showed a significantly improved event-free survival (EFS) HR of 0.4, improved pathologic and patient response rates of about 24%, and a strong trend towards overall survival (OS). This study highlights the potential for exploring different schedules and regimens in the perioperative setting.

KEYNOTE-671 had dual primary endpoints of EFS and OS. With a follow-up of 36.6 months, the trial demonstrated an EFS HR of 0.59 and a significant and clinically meaningful OS HR of 0.72 in favor of the perioperative pembrolizumab arm. While patients who achieve pathologic complete response (pCR) benefit from this therapy, some patients without pCR may also benefit from continuing treatment.

Video synopsis is AI-generated and reviewed by Targeted Oncology™ editorial staff.